Basilea Pharmaceutica AG

Asian markets mostly dropped on Wednesday. Resources shares across the region were hit by falling metals prices. Japan's Nikkei 225 fell 1.5 per cent, South Korea's Kospi shed 1.0 per cent and Hong Kong's Hang Seng Index lost 0.8 per cent. The markets also weighed down by U.S. consumer confidence and German business sentiment. But China's Shanghai Composite rebounded 1.3 per cent as monetary tightening worries eased.

Basilea Pharmaceutica AG (VTX:BSLN) Basel, Switzerland, November 13, 2008 - Basilea Pharmaceutica Ltd. announces that ceftobiprole (Zevtera(TM)), the first-in-class anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from Swissmedic for the treatment of complicated skin and soft tissue infections including diabetic foot infections.

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 27, 2008 - Multi-resistant Gram-negative bacteria are causing increasing concern around the world. Basilea's novel antibiotic BAL30072 demonstrates potent in-vitro activity against some of the most difficult to treat multi-resistant Gram-negative bacteria.

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 21, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the French Health Products Safety Agency (Agence Française de Sécurité Sanitaire des Produits de Santé [AFSSAPS]).

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 20, 2008 - New data on Basilea's late-stage anti-infectives ceftobiprole and isavuconazole will be presented at the upcoming joint meeting of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA) in Washington DC.

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 15, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by Finland's National Agency for Medicines (NAM).

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 6, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the German health authority "Bundesinstitut für Arzneimittel und Medizinprodukte" (BfArM).

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, September 22, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Danish Medicines Agency (DKMA).

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, September 15, 2008 - Basilea Pharmaceutica Ltd. announces that the Food and Drug Administration (FDA) has accepted for review the Complete Response to the ceftobiprole New Drug Application (NDA) Approvable Letter.

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, September 8, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.